Clinical Trials Logo

Filter by:
  • Completed  
  • Page [1] ·  Next »
NCT ID: NCT06289595 Completed - Pain Clinical Trials

Impact of Photobiomodulation on Pain Associated With Orthodontic Treatment

Start date: October 3, 2023
Phase:
Study type: Observational

Orthodontic treatment can cause pain. Research studies have shown that light therapy can help reduce pain that is caused by orthodontic treatment. In this study, data was collected from the medical charts of patients who had orthodontic treatment and recorded their pain levels for 1 week at the beginning of orthodontic treatment while they used a light therapy device or did not use at device. This collected information was used to see if the light therapy device could lessen orthodontic pain.

NCT ID: NCT06211816 Completed - Palliative Care Clinical Trials

Efficacy of End-of-life Communication Strategies on Nurses in the Intensive Care Unit

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Burnout among healthcare workers is frequently reported, and one of the factors cited is the stress caused by end-of-life care. It has been reported that nursing staff experience decreased well-being as a result of being involved in end-of-life care, and this is also true in intensive care units. This decrease in well-being is said to lead to lower quality of care, poor communication with patients and their families, absenteeism, and high turnover. Although palliative care interventions such as education and communication tools have been reported to improve the well-being of healthcare professionals involved in end-of-life care, few reports have evaluated the association with burnout. We investigated whether communication-based palliative interventions in end-of-life care in intensive care units (ICUs) improve the risk of burnout among nurses working in ICUs.

NCT ID: NCT06156982 Completed - COVID-19 Clinical Trials

An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan

Evusheld DBR
Start date: December 6, 2023
Phase:
Study type: Observational

This is an observational, cohort study that will use secondary data to describe the baseline demographics and clinical characteristics in patients who received EVUSHELD as PrEP against SARS-CoV-2 infection/COVID-19 in Japan. All patients who have a record of administration of EVUSHELD in the database will be included in the study. The index date will be defined as the date of first EVUSHELD administration in the database (Day 0) and the patients will be followed up to 6 months after the index date (Day 1 to 180). The look back period is defined as the 12-month period prior to index date (Day -360 to -1). The exposure of interest will be defined as the administration of EVUSHELD for use as PrEP against COVID-19. As the result of feasibility assessment, sample size of the study expected to be approximately 280.

NCT ID: NCT06144190 Completed - Length of Stay Clinical Trials

Discharge Criteria of Preterm Infants

Start date: January 1, 2020
Phase:
Study type: Observational

This retrospective study aims to compare discharge criteria and their impact on the length of stay using two neonatal intensive care units from two countries. The possible discharge criteria include temperature control, apnea observation, periodic respiration, least weight limit, and parents' readiness. The data were collected retrospectively in each study site.

NCT ID: NCT06139341 Completed - Healthy Clinical Trials

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 765845 Are Tolerated

Start date: July 21, 2023
Phase: Phase 1
Study type: Interventional

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 765845 in healthy male Japanese subjects following intravenous administration of single rising doses.

NCT ID: NCT06139302 Completed - Healthy Clinical Trials

A Study to Test How Different Doses of BI 1015550 Are Taken up in the Body of Healthy Japanese Men

Start date: December 20, 2023
Phase: Phase 1
Study type: Interventional

The main objectives of this trial are to investigate pharmacokinetics (PK) of R-BI 1015550 in Japanese healthy male subjects following oral administration of two different single BI 1015550 doses.

NCT ID: NCT06125366 Completed - Healthy Volunteers Clinical Trials

A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants

Start date: April 17, 2019
Phase: Phase 1
Study type: Interventional

The goal of this clinical study was to learn more about BAY1747846 compared to placebo when given as an injection into the vein in Japanese healthy male participants: - the safety of BAY1747846 when given at increasing single doses - the level of BAY1747846 in the body over time when given at increasing single doses. To answer the first question, the researchers compared the number and severity of medical problems the Japanese participants had after receiving BAY 1747846 at increasing doses and placebo respectively. Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments. To answer the second question, the researchers determined: - the (average) total level of BAY1747846 in the body, also called AUC - the (average) highest level of BAY1747846 in the body, also called Cmax - how BAY1747846 is removed from the body, also called clearance (CL).

NCT ID: NCT06106932 Completed - Endometriosis Clinical Trials

GnRH-a on Angiogenesis of Endometriosis

Start date: September 2015
Phase: N/A
Study type: Interventional

Purpose: Neo-angiogenesis is necessary for adhesion and invasiveness of endometriotic lesions in women affected by endometriosis. VEGF is one of the major components of angiogenesis and is part of the major pathway TF-PAR-2-VEGF that leads to neo-angiogenesis. SP1 is a transcriptional factor that has lately been studied for its crucial role in angiogenesis, via a distinct pathway. We hypothesize that by blocking angiogenetic pathways we can repress endometriotic lesions. GnRH-agonists are routinely used, especially pre-operatively, in endometriosis. It would be interesting to clarify which angiogenetic pathways are affected and pave the way for further research over anti-angiogenetic effects on endometriosis. Methods: We used qRT-PCR to study mRNA expression levels of TF, PAR-2, VEGF and SP1 in endometriotic tissues of women who underwent surgery for endometriosis and received GnRH-a [leuprolide acetate] preoperatively.

NCT ID: NCT06072118 Completed - Cadasil Clinical Trials

Adrenomedullin for CADASIL

AMCAD
Start date: January 6, 2022
Phase: Phase 2
Study type: Interventional

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common form of hereditary cerebral small vessel disease, with no proven disease-modifying treatments. Adrenomedullin, a vasoactive peptide, has angiogenic, vasodilation, anti-inflammatory, and anti-oxidative properties and could have triple sites of action on components of the neuro-glial-vascular unit consisting of vessels, microglia and oligodendrocytes or, more specifically, on the white matter oligovascular unit. The aim of the AMCAD trial is to assess the safety and efficacy of Adrenomedullin in CADASIL patients.

NCT ID: NCT06049329 Completed - Obesity Clinical Trials

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

Start date: September 14, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as an oral tablet to Japanese participants.